Behçet syndrome
Yusuf Yazıcı(Io Therapeutics (United States)), Hasan Yazıcı(Istanbul University), Gülen Hatemi(Center for Rheumatology), Bahram Bodaghi(Sorbonne Université), Noburu Suzuki(St. Marianna University School of Medicine), Jae Hee Cheon(Severance Hospital), Nicola Ambrose(University College London)
Cited by 175
Related Papers
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
2018 update of the EULAR recommendations for the management of Behçet's syndrome
|Annals of the Rheumatic Diseases|2018|771
The Long-Term Mortality and Morbidity of Behçet Syndrome
|Medicine|2003|757
EULAR recommendations for the management of Behçet disease
|Annals of the Rheumatic Diseases|2008|721
A Controlled Trial of Azathioprine in Behçet's Syndrome
|New England Journal of Medicine|1990|646